The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
·
·
{read_time} min read
Take your startup to the next level
Supercharge your business with a modern web design fine tuned for performance and conversion
Leave a Reply